You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 1326 to 1350 of about 5877
Next 25
12/29/2017
Musella Foundation awards brain tumor research grant!
Charitable giving to take a hit from the tax law
12/28/2017
Foundation Aims For Virtual Trial Registry To Help Patients With Brain Cancer Get Drugs Sooner
12/27/2017
Cancer Drug Price Rises 1,400% With No Generic to Challenge It
Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial with TSC in Glioblastoma Multiforme
12/26/2017
DelMar Pharmaceuticals announces Fast Track designation for VAL-083 in recurrent Glioblastoma
12/23/2017
Musella Foundation Co-pay Assistance Program Status
Highlights from the Society for Neuro Oncology annual meeting, San Francisco California, November 16-19 2017
12/19/2017
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
12/07/2017
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
12/06/2017
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
12/04/2017
A novel immuno-oncology approach to treating a rare childhood brain cancer
12/03/2017
Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.
Correction regarding dose of Avastin in an old article
12/02/2017
Promising target for treating brain tumors in children
Novocure (NVCR) Announces Reimbursement Approval for Optune in Japan for Treatment of Newly Diagnosed GBM
Novel Agents for GBM and Glioma From SNO 2017
Key Trials on Gliomas at SNO 2017
SNO 2017: No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers, or Defibrillators
SNO 2017: Toca 511/FC Lead to Durable Responses in IDH1 Wildtype and Mutant Recurrent High-Grade Glioma
Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma
Researchers identify vulnerability for glioblastoma subtypes
Novel Agents for GBM: A Review of Trials at SNO 2017
12/01/2017
FDA Aims to Expand Early-Approval Program for Promising Drugs